Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | TK1 | P04183 | 3/20 | 0.54 |
| ▸ | TK2 | O00142 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030380 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2030383 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL21585062 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL18214117 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2611574 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL13880679 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2611573 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL27102653 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL8165992 | 0.89 | LMNA (0.55) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL29757418 | 0.89 | TK1 (0.58) | LMNASMN1; SMN2ALOX12ADRA1ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | LG ELECTRONICS INC. (KR) | 2022-04-28 | — | — | US | disclosed |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | Singular Genomics Systems, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200340051-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2020-10-29 | — | — | US | disclosed |
| US-10738072-B1 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3091026-B1 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | CENTRILLION TECH HOLDINGS CORP (KY) | 2019-02-20 | — | — | EP | disclosed |
| US-20100190151-A1 | FLUORESCENTLY LABELED NUCLEOSIDE TRIPHOSPHATES AND ANALOGS THEREOF FOR SEQUENCING NUCLEIC ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2010-07-29 | — | — | US | disclosed |
| US-7674778-B2 | Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine | ALNYLAM PHARMACEUTICALS (US) | 2010-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200340051-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | NUDT21, CPSF7, DCLRE1A | LMNA 63/4885SMN1; SMN2 1624/4885ALOX12 3327/4885 |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | NUDT21, CPSF7, DCLRE1A | LMNA 63/4885SMN1; SMN2 1624/4885ALOX12 3327/4885 |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | LMNA 467/4885SMN1; SMN2 1787/4885ALOX12 3850/4885 |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | NUDT21, CPSF7, DCLRE1A | LMNA 63/4885SMN1; SMN2 1624/4885ALOX12 3327/4885 |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | LMNA 467/4885SMN1; SMN2 1787/4885ALOX12 3850/4885 |
| US-10738072-B1 | Nucleotide analogues | NUDT1, POLN, TYMP | LMNA 541/4885SMN1; SMN2 1337/4885ALOX12 4328/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | LMNA 467/4885SMN1; SMN2 1787/4885ALOX12 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.